Skip to main navigation
Skip to search
Skip to main content
Providence Home
Search content at Providence
Home
Profiles
Research and Focus Areas
Grants and Projects
Research
Awards
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Philip Mease
, Iain B. McInnes
Providence
Research output
:
Contribution to journal
›
Review article
›
peer-review
47
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Secukinumab: A New Treatment Option for Psoriatic Arthritis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Psoriatic Arthritis
100%
Secukinumab
100%
Treatment Option
100%
Tumor Necrosis Factor
57%
Quality of Life
28%
Interleukin 17
28%
Immunoglobulin G1
14%
Physical Disease by Body Function
14%
Clinical Study
14%
Headache
14%
Spondylarthritis
14%
Biological Therapy
14%
Psoriasis
14%
Rhinopharyngitis
14%
Upper Respiratory Tract Infection
14%
Arthropathy
14%
Rheumatology
14%
Placebo
14%
Monoclonal Antibody
14%
Methotrexate
14%
Patient-Reported Outcome
14%
Treatment Modality
14%
Pathogenesis
14%
Adverse Event
14%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriatic Arthritis
100%
Secukinumab
100%
Tumor Necrosis Factor
57%
Interleukin 17
28%
Clinical Study
14%
Placebo
14%
Adverse Event
14%
Physical Disease by Body Function
14%
Rhinopharyngitis
14%
Immunoglobulin G1
14%
Spondylarthritis
14%
Methotrexate
14%
Headache
14%
Arthropathy
14%
Monoclonal Antibody
14%
Psoriasis
14%
Upper Respiratory Tract Infection
14%
Pathogenesis
14%
Mode of Action
14%